CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Acerus Pharmaceuticals Corporation is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Acerus Pharmaceuticals Corporation
7025 Langer Drive, Suite 205
Phone: (416) 679-0771p:416 679-0771 MISSISSAUGA, ON  L5N 0E8  Canada Fax: (416) 793-2740f:416 793-2740
This company is no longer actively traded on any major stock exchange.
Business Summary
Acerus Pharmaceuticals Corporation is a Canada-based specialty pharmaceutical company. The Company is focused on the commercialization and development of prescription products, with a primary focus in the field of men's health. Its product, Natesto, a testosterone nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism. Its product pipeline includes Avanafil, Lidbree, and Tefina. Avanafil is a chemical entity, PDE5 inhibitor for the treatment of erectile dysfunction in men. Lidbree, is a short acting lidocaine formulation delivered through a proprietary device into the vaginal mucosal tissue. It also has product rights to Tefina, a clinical stage product aimed at addressing an unmet need for women with female sexual dysfunction. Its primary market is the United States, where it commercializes its product with its contract commercial provider, Syneos Health (Syneos). It commercializes its products via its own salesforce in the United States and Canada.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202212/31/2021Yes-Yes--

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board Ian O.Ihnatowycz 66 1/1/2019 9/9/2013
President, Chief Executive Officer, Director Edward J.Gudaitis 5/1/2018 5/1/2018
Vice Chairman of the Board SamHerschkowitz 3/1/2022 3/1/2022
7 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Acerus Labs Inc. 205 Langer Drive Mississauga ON Canada
Acerus Pharmaceuticals USA, LLC 205 Langer Drive Mississauga ON Canada
Serenity Pharmaceuticals, LLC 105 Hawk Lane Mildford PA United States

Business Names
Business Name
3TP
Acerus Biopharma Inc.
Acerus Labs Inc.
6 additional Business Names available in full report.

General Information
Outstanding Shares: 7,702,297 (As of 9/30/2022)
Stock Exchange: TSE
Federal Tax Id: 981229465
Fax Number: (416) 793-2740


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, October 29, 2024